MACK
Merrimack Pharmaceuticals, Inc.
MACK
MACK
Delisted
MACK was delisted on the 17th of May, 2024.
50 hedge funds and large institutions have $91M invested in Merrimack Pharmaceuticals, Inc. in 2023 Q1 according to their latest regulatory filings, with 10 funds opening new positions, 14 increasing their positions, 9 reducing their positions, and 7 closing their positions.
New
Increased
Maintained
Reduced
Closed
Holders
50
Holders Change
+3
Holders Change %
+6.38%
% of All Funds
0.8%
Holding in Top 10
2
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-33.33%
% of All Funds
0.03%
New
10
Increased
14
Reduced
9
Closed
7
Calls
$6.79M
Puts
$3.96M
Net Calls
+$2.84M
Net Calls Change
-$20K
Top Buyers
| 1 |
MAP
1
Madison Avenue Partners
New York
|
$6.8M |
| 2 |
2
Invesco
Atlanta,
Georgia
|
$2.59M |
| 3 |
WSL
3
Western Standard LLC
Los Angeles,
California
|
$20.6M |
| 4 |
NM
4
Newtyn Management
New York
|
$23M |
| 5 |
5
Marshall Wace
London,
United Kingdom
|
$1.21M |
Top Sellers
| Name | Holding | Trade Value |
Shares Change |
Shares Change % |
|
|---|---|---|---|---|---|
|
O
51
OrbiMed
New York
| – | -$843K | -73,600 | Closed |
|
|
PVI
52
Pura Vida Investments
New York
| – | -$735K | -64,100 | Closed |
|
53
Two Sigma Investments
New York
| – | -$487K | -42,490 | Closed |
|
54
Two Sigma Advisers
New York
| – | -$128K | -11,181 | Closed |
|
|
FWA
55
Freedom Wealth Alliance
Brookfield,
Wisconsin
| – | -$20.9K | -1,820 | Closed |
|
56
JPMorgan Chase & Co
New York
| – | -$4K | -354 | Closed |
|